Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Increased by HealthInvest Partners AB

HealthInvest Partners AB boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.1% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 22,012 shares of the medical research company’s stock after purchasing an additional 2,554 shares during the period. Thermo Fisher Scientific makes up approximately 6.4% of HealthInvest Partners AB’s portfolio, making the stock its 4th biggest holding. HealthInvest Partners AB’s holdings in Thermo Fisher Scientific were worth $13,616,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. EP Wealth Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 2.3% in the first quarter. EP Wealth Advisors LLC now owns 14,175 shares of the medical research company’s stock valued at $8,239,000 after purchasing an additional 316 shares during the last quarter. Westwood Holdings Group Inc. increased its position in shares of Thermo Fisher Scientific by 54.9% during the first quarter. Westwood Holdings Group Inc. now owns 1,233 shares of the medical research company’s stock valued at $717,000 after acquiring an additional 437 shares during the last quarter. Senator Investment Group LP acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at $49,403,000. Brant Point Investment Management LLC grew its position in Thermo Fisher Scientific by 1.4% in the 1st quarter. Brant Point Investment Management LLC now owns 15,025 shares of the medical research company’s stock valued at $8,733,000 after acquiring an additional 207 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Stonebridge Capital Advisors LLC now owns 24,864 shares of the medical research company’s stock valued at $14,451,000 after purchasing an additional 198 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $2.79 during mid-day trading on Thursday, hitting $510.05. The stock had a trading volume of 73,171 shares, compared to its average volume of 1,485,423. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market cap of $195.09 billion, a price-to-earnings ratio of 32.15, a P/E/G ratio of 3.37 and a beta of 0.79. The company has a 50 day simple moving average of $579.63 and a 200 day simple moving average of $580.98. Thermo Fisher Scientific Inc. has a 52-week low of $480.57 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.69 earnings per share. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Evercore ISI cut their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Sanford C. Bernstein cut their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a report on Thursday, October 24th. Finally, Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 9,000 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares in the company, valued at approximately $8,076,178.88. This trade represents a 38.12 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,150 shares of company stock valued at $20,651,865. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.